Epic Sciences

In the News

07.07.2016

Genomic Health to market Epic Sciences’ AR-V7 liquid biopsy test.

New York, GenomeWeb — Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

07.06.2016

Test aids prostate cancer treatment.

New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.

06.14.2016

Guest Commentary: Back to cancer’s drawing board.

By Murali Prahalad of Epic Sciences — A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.

06.09.2016

Epic Sciences' circulating tumor cell prostate cancer test shows promise in new JAMA study.

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences' non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.

01.28.2016

Epic, Avera ink deal to use liquid biopsy platform in clinical studies.

New York, GenomeWeb — Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

01.14.2016

Never leave a cell behind.

Rocky River, DDNews — Article covering Epic Sciences' platform technology and describes how it is being used in partnerships with outside research teams.

01.12.2016

Utility of CTC platform in prostate cancer MDx.

New York, GenomeWeb — Epic Sciences was covered in a “Featured In-Depth” story in GenomeWeb Daily News: "Epic Sciences, MSKCC Research Suggests Utility for CTC Platform in Prostate Cancer MDx."